Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current and future therapies for gout
Tristan Pascart, Pascal Richette
Expert Opinion on Pharmacotherapy (2017) Vol. 18, Iss. 12, pp. 1201-1211
Closed Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Inflammasome biology, molecular pathology and therapeutic implications
Fawaz Awad, Eman Assrawi, Camille Louvrier, et al.
Pharmacology & Therapeutics (2018) Vol. 187, pp. 133-149
Closed Access | Times Cited: 117
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update
Arrigo F.G. Cicero, Federica Fogacci, Masanari Kuwabara, et al.
Medicina (2021) Vol. 57, Iss. 1, pp. 58-58
Open Access | Times Cited: 79
Review: Cell Death, Nucleic Acids, and Immunity
Keith B. Elkon
Arthritis & Rheumatology (2018) Vol. 70, Iss. 6, pp. 805-816
Open Access | Times Cited: 82
Investigational drugs for hyperuricemia, an update on recent developments
Tristan Pascart, Pascal Richette
Expert Opinion on Investigational Drugs (2018) Vol. 27, Iss. 5, pp. 437-444
Closed Access | Times Cited: 72
<p>Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications</p>
Min Gong, Song Wen, Thiquynhnga Nguyen, et al.
Diabetes Metabolic Syndrome and Obesity (2020) Vol. Volume 13, pp. 943-962
Open Access | Times Cited: 66
Mechanisms impairing blood pressure responses to nitrite and nitrate
Gustavo H. Oliveira‐Paula, Lucas C. Pinheiro, José E. Tanus‐Santos
Nitric Oxide (2019) Vol. 85, pp. 35-43
Open Access | Times Cited: 47
Pharmacologic inducers of the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis
Bojana Ristić, Mohd Omar Faruk Sikder, Yangzom D. Bhutia, et al.
Asian Journal of Pharmaceutical Sciences (2019) Vol. 15, Iss. 2, pp. 173-180
Open Access | Times Cited: 46
Two different synchronous spectrofluorimetric approaches for simultaneous determination of febuxostat and ibuprofen
Galal Magdy, Fathalla Belal, Ahmed M. Abdel‐Megied, et al.
Royal Society Open Science (2021) Vol. 8, Iss. 5, pp. 210354-210354
Open Access | Times Cited: 40
Preparation, characterisation, and pharmacodynamic study of myricetin pH-sensitive liposomes
Chenlu Li, Mengzhe Du, Lingzhi Meng, et al.
Journal of Microencapsulation (2024) Vol. 41, Iss. 4, pp. 269-283
Closed Access | Times Cited: 5
Amitriptyline blocks innate immune responses mediated by toll‐like receptor 4 and IL‐1 receptor: Preclinical and clinical evidence in osteoarthritis and gout
Eloi Franco‐Trepat, Ana Alonso‐Pérez, María Guillán‐Fresco, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 2, pp. 270-286
Open Access | Times Cited: 28
Effects of lobetyolin on xanthine oxidase activity in vitro and in vivo: weak and mixed inhibition
In‐Soo Yoon, Seung‐Sik Cho
Natural Product Research (2019) Vol. 35, Iss. 10, pp. 1667-1670
Closed Access | Times Cited: 31
Canakinumab and cardiovascular outcomes: results of the CANTOS trial
Syed Raza Shah, Zainab Abbasi, Mazia Fatima, et al.
Journal of Community Hospital Internal Medicine Perspectives (2018) Vol. 8, Iss. 1, pp. 21-22
Open Access | Times Cited: 32
Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval
Tristan Pascart, Laurène Norberciak, Hang‐Korng Ea, et al.
Lara D. Veeken (2019) Vol. 58, Iss. 12, pp. 2181-2187
Closed Access | Times Cited: 26
Interrogation of the perturbed gut microbiota in gouty arthritis patients through in silico metabolic modeling
Michael A. Henson
Engineering in Life Sciences (2021) Vol. 21, Iss. 7, pp. 489-501
Open Access | Times Cited: 21
β Boswellic Acid Blocks Articular Innate Immune Responses: An In Silico and In Vitro Approach to Traditional Medicine
Eloi Franco‐Trepat, Ana Alonso‐Pérez, María Guillán‐Fresco, et al.
Antioxidants (2023) Vol. 12, Iss. 2, pp. 371-371
Open Access | Times Cited: 8
Gout Management Using Nanocarrier Systems: A Review
Chia Wen Qi, Ummu Umaimah Mohd Nordin, Syed Mahmood, et al.
ACS Applied Nano Materials (2024) Vol. 7, Iss. 9, pp. 9816-9846
Closed Access | Times Cited: 3
Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout
Jun Huang, Zehao Zhou, Mengze Zhou, et al.
Bioorganic & Medicinal Chemistry (2018) Vol. 26, Iss. 8, pp. 1653-1664
Closed Access | Times Cited: 26
Nitrite-stimulated Gastric Formation of S-nitrosothiols As An Antihypertensive Therapeutic Strategy
Gustavo H. Oliveira‐Paula, José E. Tanus‐Santos
Current Drug Targets (2018) Vol. 20, Iss. 4, pp. 431-443
Closed Access | Times Cited: 26
The citrus flavanone naringenin reduces gout-induced joint pain and inflammation in mice by inhibiting the activation of NFκB and macrophage release of IL-1β
Kenji W. Ruiz-Miyazawa, Sérgio M. Borghi, Felipe A. Pinho‐Ribeiro, et al.
Journal of Functional Foods (2018) Vol. 48, pp. 106-116
Open Access | Times Cited: 23
Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: a retrospective study of 33 cases
M. Thomas, Marine Forien, Élisabeth Palazzo, et al.
Clinical Rheumatology (2018) Vol. 38, Iss. 2, pp. 425-430
Closed Access | Times Cited: 22
New drug targets for the treatment of gout arthritis: what’s new?
Tiago H. Zaninelli, Geovana Martelossi-Cebinelli, Telma Saraiva‐Santos, et al.
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 8, pp. 679-703
Closed Access | Times Cited: 6
What are the core recommendations for gout management in first line and specialist care? Systematic review of clinical practice guidelines
Brooke Conley, Samantha Bunzli, Jonathan Bullen, et al.
BMC Rheumatology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 5
A sensitive HPLC-FL method to simultaneously determine febuxostat and diclofenac in rat plasma: assessment of metabolic drug interactions in vitro and in vivo
Dong‐Gyun Han, Kyu-Sang Kim, Seong‐Wook Seo, et al.
Analytical Methods (2020) Vol. 12, Iss. 16, pp. 2166-2175
Closed Access | Times Cited: 13
Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients
Celine Johanna van de Laar, Carly A. Janssen, M. Janssen, et al.
PLoS ONE (2022) Vol. 17, Iss. 1, pp. e0261940-e0261940
Open Access | Times Cited: 9
A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China
Heng Cheng, Dewen Yan, Xin Zuo, et al.
Pharmacogenetics and Genomics (2018) Vol. 28, Iss. 5, pp. 117-124
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top